Cassie J. Clarke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cassie J. Clarke has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Jim C. Norman
Cancer Research UK Scotland Institute 1 , Glasgow
44 shared publications - Colin Nixon
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
43 shared publications - Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
43 shared publications - Declan Whyte
Erasmus University Medical Center 1 Department of Pulmonary Medicine Rotterdam, the Netherlands
41 shared publications - Leo M. Carlin
Cancer Research UK Scotland Institute, Glasgow, UK
41 shared publications - Rene Jackstadt
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGMBH), Heidelberg, Germany
41 shared publications
Latest Publications
- Open Access
Cholesterol and p53 promote senescence and systemic fibrosis in metabolic dysfunction-associated steatohepatitis
Background & aims: TP53 (p53) coordinates diverse cellular stress response programmes including pro-survival activities, senescence, and cell death. During tissue damage, p53 can shape both the local cellular response to injury, including the fibrotic response, and influence distal organ biology. Fibrosis in the liver is a major driver of hepatocellular carcinoma (HCC) risk within metabolic dysfunction-associated steatohepatitis (MASH). It is also an important determinant of dysfunction in multiple distal tissues including the kidneys, lungs, and heart. Despite significant clinical burden, our understanding of the molecular determinants of fibrotic MASH and its relationship to multiorgan fibrosis remain incomplete. Here, we investigate local and systemic effects of hepatocellular p53 activity and cholesterol during MASH development, with implications for disease prevention. Methods: This study utilised a genetic model of stabilised p53, diet-induced MASH models with varying cholesterol compositions, and an in vitro obesogenic system to investigate p53 activity during liver disease development. Non-invasive imaging and histopathological analyses were employed to monitor p53 activity, MASH, and multiorgan fibrosis in vivo . Complementary approaches, including in vitro human multicomponent liver spheroids, cytokine arrays, and analyses of human MASH transcriptomic and proteomic datasets, were used to examine molecular drivers and patient relevance. Results: Using an inducible mouse model of MDM2 E3 ubiquitin ligase deficiency to stabilise p53, we report that hepatocellular MDM2 E3 loss results in progressive fibrotic damage, robust hepatocellular expression of the p53 target gene CDKN1A/p21 (p21),and induces p21 and fibrosis in the kidneys of male mice in a sex-specific manner. In diet-induced MASH, we observe cholesterol and p53-dependent development of liver fibrosis, high expression of hepatocellular p21, and induction of p21 and fibrosis in the kidneys of male mice—reminiscent of features observed in MDM2 E3-deficient mice. We also observe fibrosis in the lungs and heart of male MASH mice. Both a cholesterol-free obesogenic diet and liver-specific loss of p53 mitigate hepatic fibrosis and systemic induction of p21 and fibrosis. Mechanistically, p53 induces hepatic expression of senescence-associated secretory phenotype (SASP) factors, including GDF15, in vivo . A human multicomponent LiverACE spheroid model showed a concordant trend towards increased GDF15 protein abundance under steatotic stress, while in humans, elevated circulating GDF15 levels in advanced MASH correlate with increased TNFRSF1A and EPHA2, circulating markers linked to kidney injury. Conclusions: Our work identifies undue p53 activity within the liver as a driver of multiorgan fibrosis in a sex-specific manner, affecting male but not female mice. We implicate cholesterol in promoting this pro-fibrotic environment in vivo and highlight circulating factors that could identify at-risk patients for multiorgan fibrosis in MASH. IMPACT AND IMPLICATIONS: P53 is a potent tumour suppressor that is frequently mutated or lost in HCC. Our findings suggest that dietary cholesterol promotes detrimental overactivation of p53 in MASH and facilitates fibrosis within the liver and distal organs. Further studies evaluating the efficacy of targeting hepatic p53 in combination with dietary or weight loss interventions could provide new treatment approaches for systemic fibrosis and MASH.
Open AccessCholesterol and p53 promote senescence and systemic fibrosis in metabolic dysfunction-associated steatohepatitis
Background & aims: TP53 (p53) coordinates diverse cellular stress response programmes including pro-survival activities, senescence, and cell death. During tissue damage, p53 can shape both the local cellular response to injury, including the fibrotic response, and influence distal organ biology. Fibrosis in the liver is a major driver of hepatocellular carcinoma (HCC) risk within metabolic dysfunction-associated steatohepatitis (MASH). It is also an important determinant of dysfunction in multiple distal tissues including the kidneys, lungs, and heart. Despite significant clinical burden, our understanding of the molecular determinants of fibrotic MASH and its relationship to multiorgan fibrosis remain incomplete. Here, we investigate local and systemic effects of hepatocellular p53 activity and cholesterol during MASH development, with implications for disease prevention. Methods: This study utilised a genetic model of stabilised p53, diet-induced MASH models with varying cholesterol compositions, and an in vitro obesogenic system to investigate p53 activity during liver disease development. Non-invasive imaging and histopathological analyses were employed to monitor p53 activity, MASH, and multiorgan fibrosis in vivo . Complementary approaches, including in vitro human multicomponent liver spheroids, cytokine arrays, and analyses of human MASH transcriptomic and proteomic datasets, were used to examine molecular drivers and patient relevance. Results: Using an inducible mouse model of MDM2 E3 ubiquitin ligase deficiency to stabilise p53, we report that hepatocellular MDM2 E3 loss results in progressive fibrotic damage, robust hepatocellular expression of the p53 target gene CDKN1A/p21 (p21),and induces p21 and fibrosis in the kidneys of male mice in a sex-specific manner. In diet-induced MASH, we observe cholesterol and p53-dependent development of liver fibrosis, high expression of hepatocellular p21, and induction of p21 and fibrosis in the kidneys of male mice—reminiscent of features observed in MDM2 E3-deficient mice. We also observe fibrosis in the lungs and heart of male MASH mice. Both a cholesterol-free obesogenic diet and liver-specific loss of p53 mitigate hepatic fibrosis and systemic induction of p21 and fibrosis. Mechanistically, p53 induces hepatic expression of senescence-associated secretory phenotype (SASP) factors, including GDF15, in vivo . A human multicomponent LiverACE spheroid model showed a concordant trend towards increased GDF15 protein abundance under steatotic stress, while in humans, elevated circulating GDF15 levels in advanced MASH correlate with increased TNFRSF1A and EPHA2, circulating markers linked to kidney injury. Conclusions: Our work identifies undue p53 activity within the liver as a driver of multiorgan fibrosis in a sex-specific manner, affecting male but not female mice. We implicate cholesterol in promoting this pro-fibrotic environment in vivo and highlight circulating factors that could identify at-risk patients for multiorgan fibrosis in MASH. IMPACT AND IMPLICATIONS: P53 is a potent tumour suppressor that is frequently mutated or lost in HCC. Our findings suggest that dietary cholesterol promotes detrimental overactivation of p53 in MASH and facilitates fibrosis within the liver and distal organs. Further studies evaluating the efficacy of targeting hepatic p53 in combination with dietary or weight loss interventions could provide new treatment approaches for systemic fibrosis and MASH.
- Open Access
- 17 August 2026
- Published by MDPI AG in Hematology Reports
- Vol. 18 (4) , 59
The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel
Background/Objectives: Revolutionary small molecule, targeted, tyrosine kinase inhibitors (TKIs) in the clinic have engendered the perception that optimal treatment has already been established for diseases like chronic myeloid leukemia (CML). Addressing BCR::ABL1 oncokinase domain mutations in CML is unlikely to redress disease recrudescence owing to persistent leukemia stem cells (LSCs). Therefore, it is necessary to consider an alternative strategic approach: disrupting LSC interactions with the protective microenvironment and/or immune system. The interaction of the TNF-α superfamily member, CD27, with its upregulated ligand, CD70, initiates survival signaling specifically in CML cells when BCR::ABL1 is inhibited by TKIs and thus represents an attractive target. Previous studies modulating the expression of CD27 on LSCs in a mouse model of advanced phase CML were encouraging. In our study, we explored the CD70/CD27 axis as a therapeutic target in early-phase disease. Methods: Primitive CD34+ cells from treatment-naïve chronic phase (CP) CML patients were drug-exposed in an in vitro co-culture system; combination drug treatments of the therapeutic anti-CD70 antibody and TKIs, nilotinib, were assessed in our CP CML murine model. Results: The blockade of the CD70/CD27 axis in combination with TKIs did not result in greater LSC elimination than with nilotinib as a single agent in our CP CML models. Nonetheless, there was an observed reduction in CD70+ cells with combination treatment. Conclusion: Further preclinical study of the antibody as an adjunct in CD70-expressing hematological malignancy is perhaps warranted.
- 17 August 2026
- Published by MDPI AG in Hematology Reports
- Vol. 18 (4) , 59
Open AccessThe CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel
Background/Objectives: Revolutionary small molecule, targeted, tyrosine kinase inhibitors (TKIs) in the clinic have engendered the perception that optimal treatment has already been established for diseases like chronic myeloid leukemia (CML). Addressing BCR::ABL1 oncokinase domain mutations in CML is unlikely to redress disease recrudescence owing to persistent leukemia stem cells (LSCs). Therefore, it is necessary to consider an alternative strategic approach: disrupting LSC interactions with the protective microenvironment and/or immune system. The interaction of the TNF-α superfamily member, CD27, with its upregulated ligand, CD70, initiates survival signaling specifically in CML cells when BCR::ABL1 is inhibited by TKIs and thus represents an attractive target. Previous studies modulating the expression of CD27 on LSCs in a mouse model of advanced phase CML were encouraging. In our study, we explored the CD70/CD27 axis as a therapeutic target in early-phase disease. Methods: Primitive CD34+ cells from treatment-naïve chronic phase (CP) CML patients were drug-exposed in an in vitro co-culture system; combination drug treatments of the therapeutic anti-CD70 antibody and TKIs, nilotinib, were assessed in our CP CML murine model. Results: The blockade of the CD70/CD27 axis in combination with TKIs did not result in greater LSC elimination than with nilotinib as a single agent in our CP CML models. Nonetheless, there was an observed reduction in CD70+ cells with combination treatment. Conclusion: Further preclinical study of the antibody as an adjunct in CD70-expressing hematological malignancy is perhaps warranted.
- Open Access
- 23 July 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (17) , 4248-4282
Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes
Understanding mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis. Here we identify uracil as a metastasis-associated metabolite in genetically engineered mouse models of cancer and in patients with metastatic breast cancer. Uracil is generated by the enzyme uridine phosphorylase-1 (UPP1), and we find that neutrophils are a significant source of UPP1 in metastatic cancer. Mammary tumours increase expression of adhesion molecules on the neutrophil surface, in a UPP1-dependent manner, leading to decreased neutrophil motility in the pre-metastatic lung. UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil increases fibronectin deposition in the extracellular microenvironment. Knockout or inhibition of UPP1 in mice with mammary tumours increases T-cell numbers and reduces fibronectin content in the lung, and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung, and suggest that circulating uracil could be a marker of metastasis, and that pharmacological inhibition of UPP1 could be a strategy to reduce recurrence.
- 23 July 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (17) , 4248-4282
Open AccessUridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes
Understanding mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis. Here we identify uracil as a metastasis-associated metabolite in genetically engineered mouse models of cancer and in patients with metastatic breast cancer. Uracil is generated by the enzyme uridine phosphorylase-1 (UPP1), and we find that neutrophils are a significant source of UPP1 in metastatic cancer. Mammary tumours increase expression of adhesion molecules on the neutrophil surface, in a UPP1-dependent manner, leading to decreased neutrophil motility in the pre-metastatic lung. UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil increases fibronectin deposition in the extracellular microenvironment. Knockout or inhibition of UPP1 in mice with mammary tumours increases T-cell numbers and reduces fibronectin content in the lung, and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung, and suggest that circulating uracil could be a marker of metastasis, and that pharmacological inhibition of UPP1 could be a strategy to reduce recurrence.
- Open Access
- 9 June 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (8)
Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironments
Altered cellular metabolism has been associated with the acquisition of invasive phenotypes during metastasis. To study this, we combined a genetically engineered mouse model of mammary carcinoma with syngeneic transplantation and primary tumor resection to generate isogenic cells from primary tumors and their corresponding lung micrometastases. Metabolic analyses indicated that micrometastatic cells increase proline production at the expense of glutathione synthesis, leading to a reduction in total glutathione levels. Micrometastatic cells also have altered sphingomyelin metabolism, leading to increased intracellular levels of specific ceramides. The combination of these metabolic adaptations alters extracellular vesicle (EV) production to render the microenvironment more permissive for invasion. Indeed, micrometastatic cells shut down Rab27-dependent production of EVs and, instead, switch on neutral sphingomyelinase-2 (nSM2)-dependent EV release. EVs released in an nSM2-dependent manner from micrometastatic cells, in turn, influence the ability of fibroblasts to deposit extracellular matrix, which promotes cancer cell invasiveness. These data provide evidence that metabolic rewiring drives invasive processes in metastasis by influencing EV release.
- 9 June 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (8)
Open AccessMetabolic adaptations of micrometastases alter EV production to generate invasive microenvironments
Altered cellular metabolism has been associated with the acquisition of invasive phenotypes during metastasis. To study this, we combined a genetically engineered mouse model of mammary carcinoma with syngeneic transplantation and primary tumor resection to generate isogenic cells from primary tumors and their corresponding lung micrometastases. Metabolic analyses indicated that micrometastatic cells increase proline production at the expense of glutathione synthesis, leading to a reduction in total glutathione levels. Micrometastatic cells also have altered sphingomyelin metabolism, leading to increased intracellular levels of specific ceramides. The combination of these metabolic adaptations alters extracellular vesicle (EV) production to render the microenvironment more permissive for invasion. Indeed, micrometastatic cells shut down Rab27-dependent production of EVs and, instead, switch on neutral sphingomyelinase-2 (nSM2)-dependent EV release. EVs released in an nSM2-dependent manner from micrometastatic cells, in turn, influence the ability of fibroblasts to deposit extracellular matrix, which promotes cancer cell invasiveness. These data provide evidence that metabolic rewiring drives invasive processes in metastasis by influencing EV release.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Signaling patterns in CRCLM. A and B, Outgoing and incoming signaling patterns in CRCLM. C, Cellular roles as dominant senders (sources) and receivers (targets) in CRCPT and LM. CRCPT dataset did not contain any Tregs or neutrophils. D, UMAP plot of neutrophil subtypes in CRCLM. E, Interaction strength of the global communication patterns between neutrophil, T-cell, and macrophage subtypes. F–I, Outgoing signal strengths from TXNIP+ neutrophils, SPP1+ macrophages, M1- and M2-like macrophages, respectively. J, The contribution of each L-R pair to the overall CXCL signaling pathway among macrophage, neutrophil, and T-cell subtypes. K–M, Visualization of the cell-cell communication patterns mediated by the most significant L-R pairs in CXCL pathway. N, Heat map showing the relative strengths of the significant outgoing and incoming signaling patterns in all communication pathways with dominant sender and receiver immune cell subtypes. The top colored bar plot represents the sum of column of values displayed in the heat map representing the different cell populations. The right gray bar plots represents the sum of row of values, representing the different signaling pathways.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Signaling patterns in CRCLM. A and B, Outgoing and incoming signaling patterns in CRCLM. C, Cellular roles as dominant senders (sources) and receivers (targets) in CRCPT and LM. CRCPT dataset did not contain any Tregs or neutrophils. D, UMAP plot of neutrophil subtypes in CRCLM. E, Interaction strength of the global communication patterns between neutrophil, T-cell, and macrophage subtypes. F–I, Outgoing signal strengths from TXNIP+ neutrophils, SPP1+ macrophages, M1- and M2-like macrophages, respectively. J, The contribution of each L-R pair to the overall CXCL signaling pathway among macrophage, neutrophil, and T-cell subtypes. K–M, Visualization of the cell-cell communication patterns mediated by the most significant L-R pairs in CXCL pathway. N, Heat map showing the relative strengths of the significant outgoing and incoming signaling patterns in all communication pathways with dominant sender and receiver immune cell subtypes. The top colored bar plot represents the sum of column of values displayed in the heat map representing the different cell populations. The right gray bar plots represents the sum of row of values, representing the different signaling pathways.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Healthy- and Tumor-enriched neutrophil signatures in human and mouse
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Healthy- and Tumor-enriched neutrophil signatures in human and mouse
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Characterization of neutrophils in metastasis. A, UMAP of neutrophils in CRCLM. B, Coexpression of H_enriched and T_enriched signatures. One cluster is not enriched for either signature (blue arrow). C and D, Unsupervised pseudotime analysis and estimated smoothers for TXNIP expression over the different numbered pseudotime lineages. E, Coexpression of TXNIP and CXCR2. F and G, Expression and estimated smoothers for CXCL8 over pseudotime. H, Coexpression of CXCL8 and IL1β. I, IHC staining of TXNIP in a patient CRCLM sample at 4x (left) and 10x (right). Scale bars = 50 µm. J and K, IHC staining of ITGAM (Neutrophils) and CD3 (T cells) in a patient CRCLM sample at 4x, scale bars = 50 µm. Dashed squares indicate regions where immune cells cluster. L, Differentially expressed genes in metastasis-specific neutrophil cluster. M, H_enriched, T_enriched, and M_enriched gene signatures in mouse bulk-RNA-seq neutrophil dataset. L, Healthy liver tissue, PT: Primary tumor, LMET: Liver metastasis. N, Averaged expression of the individual genes of the three signatures. O, UMAP plot of integrated human neutrophils from PT and metastatic (M) datasets of different cancers. P, Coexpression of CXCR2 with IL1β (top) and TXNIP (bottom). Q, Differential gene expression between neutrophils in malignancy compared with PT. R and S, GO and KEGG analysis of M_CRC neutrophils.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Characterization of neutrophils in metastasis. A, UMAP of neutrophils in CRCLM. B, Coexpression of H_enriched and T_enriched signatures. One cluster is not enriched for either signature (blue arrow). C and D, Unsupervised pseudotime analysis and estimated smoothers for TXNIP expression over the different numbered pseudotime lineages. E, Coexpression of TXNIP and CXCR2. F and G, Expression and estimated smoothers for CXCL8 over pseudotime. H, Coexpression of CXCL8 and IL1β. I, IHC staining of TXNIP in a patient CRCLM sample at 4x (left) and 10x (right). Scale bars = 50 µm. J and K, IHC staining of ITGAM (Neutrophils) and CD3 (T cells) in a patient CRCLM sample at 4x, scale bars = 50 µm. Dashed squares indicate regions where immune cells cluster. L, Differentially expressed genes in metastasis-specific neutrophil cluster. M, H_enriched, T_enriched, and M_enriched gene signatures in mouse bulk-RNA-seq neutrophil dataset. L, Healthy liver tissue, PT: Primary tumor, LMET: Liver metastasis. N, Averaged expression of the individual genes of the three signatures. O, UMAP plot of integrated human neutrophils from PT and metastatic (M) datasets of different cancers. P, Coexpression of CXCR2 with IL1β (top) and TXNIP (bottom). Q, Differential gene expression between neutrophils in malignancy compared with PT. R and S, GO and KEGG analysis of M_CRC neutrophils.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
CD4+ T cells are transcriptomically altered in metastasis. A and B, UMAP plots of CD4+ and CD8+ T cells in PT and LM grouped by cell type and tumor type, respectively. C, Differential gene expression of CD4+ T cells in LM compared with PT. D and E, GO and KEGG analyses of metastatic CD4+ T cells. F and G, Global cell-cell communication network and the interaction strengths between neutrophils, CD4+, CD8+, and Tregs. H–J, The contribution of each L-R pair to the overall signaling pathway for CXCL, IL1, and TNF pathways. K–M, Visualization of the cell-cell communication patterns mediated by each significant L-R pair for the three pathways.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
CD4+ T cells are transcriptomically altered in metastasis. A and B, UMAP plots of CD4+ and CD8+ T cells in PT and LM grouped by cell type and tumor type, respectively. C, Differential gene expression of CD4+ T cells in LM compared with PT. D and E, GO and KEGG analyses of metastatic CD4+ T cells. F and G, Global cell-cell communication network and the interaction strengths between neutrophils, CD4+, CD8+, and Tregs. H–J, The contribution of each L-R pair to the overall signaling pathway for CXCL, IL1, and TNF pathways. K–M, Visualization of the cell-cell communication patterns mediated by each significant L-R pair for the three pathways.
- Open Access
Uridine Phosphorylase-1 supports metastasis of mammary cancer by altering immune and extracellular matrix landscapes of the lung
Summary: Understanding the mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis – the leading cause of cancer-related death. Using whole animal screens in genetically engineered mouse models of cancer we have identified circulating metabolites associated with metastasis. Specifically, we highlight the pyrimidine uracil as a prominent metastasis-associated metabolite. Uracil is generated by neutrophils expressing the enzyme uridine phosphorylase-1 (UPP1), and neutrophil specific Upp1 expression is increased in cancer. Altered UPP1 activity influences expression of adhesion molecules on the surface of neutrophils, leading to decreased neutrophil motility in the pre-metastatic lung. Furthermore, we find that UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil can increase fibronectin deposition in the extracellular microenvironment. Consistently, knockout or inhibition of UPP1 in mice with mammary tumours increases the number of T-cells and reduces fibronectin content in the lung and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung and suggest that pharmacological targeting of this pathway could be an effective strategy to reduce metastasis.
Open AccessUridine Phosphorylase-1 supports metastasis of mammary cancer by altering immune and extracellular matrix landscapes of the lung
Summary: Understanding the mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis – the leading cause of cancer-related death. Using whole animal screens in genetically engineered mouse models of cancer we have identified circulating metabolites associated with metastasis. Specifically, we highlight the pyrimidine uracil as a prominent metastasis-associated metabolite. Uracil is generated by neutrophils expressing the enzyme uridine phosphorylase-1 (UPP1), and neutrophil specific Upp1 expression is increased in cancer. Altered UPP1 activity influences expression of adhesion molecules on the surface of neutrophils, leading to decreased neutrophil motility in the pre-metastatic lung. Furthermore, we find that UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil can increase fibronectin deposition in the extracellular microenvironment. Consistently, knockout or inhibition of UPP1 in mice with mammary tumours increases the number of T-cells and reduces fibronectin content in the lung and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung and suggest that pharmacological targeting of this pathway could be an effective strategy to reduce metastasis.
- Open Access
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Table S1: Mouse data for ScRNAsequencingTable S2: Primer sequences for qPCRTable S3. Top 5 markers in the integrated mouse dataset neutrophil clustersTable S4: Pseudotime Lineages of the Neutrophil datasetsTable S5: Lineage-specific differentialy expressed genes (Start Vs End) in PYMT dataset.Table S6: Lineage-specific differentialy expressed genes (Start Vs End) in CRC dataset.Table S7: Lineage-specific differentialy expressed genes (Start Vs End) in human NSCLC dataset.Table S8. Top 10 markers in the human CRCLM dataset neutrophil clustersTable S9: Top 10 Differentially expressed genes in neutrophils derived from primary tumors and metastatic tissue.Table S10: Differentially expressed genes in CRCLM neutrophilsTable S11: Differentially expressed genes in CD4 T cells in LM vs PTTable S12: Differentially expressed genes in CD8 T cells in LM vs PTTable S13: Differentially expressed genes in CD4 T cells in LM vs PT used in KEGG analysis(Threshold >3)Table S14: Description of the different neutrophil subtypes identified in CRCLM
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Characterizing Neutrophil Subtypes in Cancer Using scRNA Sequencing Demonstrates the Importance of IL1β/CXCR2 Axis in Generation of Metastasis-specific Neutrophils
Table S1: Mouse data for ScRNAsequencingTable S2: Primer sequences for qPCRTable S3. Top 5 markers in the integrated mouse dataset neutrophil clustersTable S4: Pseudotime Lineages of the Neutrophil datasetsTable S5: Lineage-specific differentialy expressed genes (Start Vs End) in PYMT dataset.Table S6: Lineage-specific differentialy expressed genes (Start Vs End) in CRC dataset.Table S7: Lineage-specific differentialy expressed genes (Start Vs End) in human NSCLC dataset.Table S8. Top 10 markers in the human CRCLM dataset neutrophil clustersTable S9: Top 10 Differentially expressed genes in neutrophils derived from primary tumors and metastatic tissue.Table S10: Differentially expressed genes in CRCLM neutrophilsTable S11: Differentially expressed genes in CD4 T cells in LM vs PTTable S12: Differentially expressed genes in CD8 T cells in LM vs PTTable S13: Differentially expressed genes in CD4 T cells in LM vs PT used in KEGG analysis(Threshold >3)Table S14: Description of the different neutrophil subtypes identified in CRCLM